Evidence map›Paper›PMID 39975526›Full record

ArticleJournal of biomedical physics & engineering2025

Simplifying Radiomics Workflow for Predicting Grade of Glioma: An Approach for Rapid and Reproducible Radiomics.

Yunus Soleymani, Peyman Sheikhzadeh, Mohammad Mohammadzadeh, Davood Khezerloo

Abstract read
In one paragraph

Article in Journal of biomedical physics & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yunus SoleymaniDepartment of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Peyman SheikhzadehDepartment of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad MohammadzadehDepartment of Radiology and Radiotherapy, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Davood KhezerlooDepartment of Radiology, Faculty of Alliance Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Radiomics with single Region of Interest (ROI) and single-sequence Magnetic Resonance Imaging (MRI) may facilitate the segmentation reproducibility and radiomics workflow due to a time-consuming and complicated delineation of that in multi-sequence MRI images. Objective: This study aimed to evaluate the performance of the radiomics approach in grading glioma based on a single-ROI delineation as Gross Tumor Volume (GTV) in a single - sequence as contrast-enhanced T1-weighted MRI. Material and Methods: This retrospective study was conducted on contrast-enhanced T1 weighted (CE T1W) MRI images of 60 grade II and 60 grade III glioma patients. The GTV regions were manually delineated. Radiomics features were extracted per patient. The segmentation reproducibility of the robust features was evaluated in several repetitions of GTV delineation. Finally, a linear Support Vector Machine (SVM) assessed the classification performance of the robust features. Results: Four significant robust features were selected for training the model ( Conclusion: High predicting power for glioma grading can be achieved with radiomics analysis by a single-ROI delineated on a single-sequence MRI image (CE T1W). In addition, single-ROI segmentation can increase radiomics reproducibility.

Indexed as

GliomaMachine LearningMagnetic Resonance ImagingRadiomicsRadiomics Reproducibility

Identifiers

PMID39975526
PMCPMC11833161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.